AOB - Board Liaison to Closed Generic discussion
Hi Councillors: I have been asked to nominate a brief discussion topic for AOB: the provision of a Board Liaison to the GAC-Council Closed Generics Team. This issue was discussed during a recent RySG meeting with the idea that a Board liaison would be beneficial. Some in that meeting thought that there was an existing provision for a Board liaison. In any case, there have have been no Board member attendance at the Closed Generics' meetings. For our Council discussion, I would like to get an understanding as to: * whether a Board liaison is already expected (and so we should remind the Board of this) * if not, whether we should request the Board to appoint a liaison (please check with your Closed Generic rep on this), and * to address an associated topic, whether the Board liaison should be dis-interested or new to the issue to provide an uncoloured perspective. If this can be simply settled or answered via an email discussion, that would be fine also. Thanks everyone and best regards, Kurt
Kurt, This certainly seems like a good idea. I would suggest that the Board might want to appoint the liaison from Sub Pro. (Was that Avri?) The topic was covered so extensively in Sub Pro deliberations and the background on those discussions would be helpful. Anne Anne E. Aikman-Scalese Of Counsel AAikman@lewisroca.com<mailto:AAikman@lewisroca.com> D. 520.629.4428 [cid:image002.png@01D8F461.3C50C140] From: council <council-bounces@gnso.icann.org> On Behalf Of kurt kjpritz.com via council Sent: Wednesday, November 9, 2022 2:58 PM To: GNSO Council List <council@gnso.icann.org> Subject: [council] AOB - Board Liaison to Closed Generic discussion [EXTERNAL] ________________________________ Hi Councillors: I have been asked to nominate a brief discussion topic for AOB: the provision of a Board Liaison to the GAC-Council Closed Generics Team. This issue was discussed during a recent RySG meeting with the idea that a Board liaison would be beneficial. Some in that meeting thought that there was an existing provision for a Board liaison. In any case, there have have been no Board member attendance at the Closed Generics' meetings. For our Council discussion, I would like to get an understanding as to: * whether a Board liaison is already expected (and so we should remind the Board of this) * if not, whether we should request the Board to appoint a liaison (please check with your Closed Generic rep on this), and * to address an associated topic, whether the Board liaison should be dis-interested or new to the issue to provide an uncoloured perspective. If this can be simply settled or answered via an email discussion, that would be fine also. Thanks everyone and best regards, Kurt ________________________________ This message and any attachments are intended only for the use of the individual or entity to which they are addressed. If the reader of this message or an attachment is not the intended recipient or the employee or agent responsible for delivering the message or attachment to the intended recipient you are hereby notified that any dissemination, distribution or copying of this message or any attachment is strictly prohibited. If you have received this communication in error, please notify us immediately by replying to the sender. The information transmitted in this message and any attachments may be privileged, is intended only for the personal and confidential use of the intended recipients, and is covered by the Electronic Communications Privacy Act, 18 U.S.C. ?2510-2521.
Kurt, Thanks for raising the issue of a possible Board Liaison to the GAC-Council Closed Generics Team. The Board’s Framing Paper<https://urldefense.proofpoint.com/v2/url?u=https-3A__www.icann.org_en_system...> from March anticipated on page 7 that, as the process came together, GAC and GNSO representatives could give further consideration to the utility of having a Board Liaison to the work. I agree that a Board Liaison would be useful so that the process reflects the Board’s request of achieving a balanced outcome. The transparency and direct lines of communication will be useful as well. As the participant in the dialogue from Council leadership, I will make sure to update participants with any discussion coming from the GNSO Council and I will raise this issue with the participants on our next call. I look forward to updating Council as additional information is available. Kind regards, John From: council <council-bounces@gnso.icann.org> On Behalf Of Aikman-Scalese, Anne via council Sent: Wednesday, November 9, 2022 7:32 PM To: kurt kjpritz.com <kurt@kjpritz.com>; GNSO Council List <council@gnso.icann.org> Subject: Re: [council] AOB - Board Liaison to Closed Generic discussion ◄External Email► - From: council-bounces@gnso.icann.org<mailto:council-bounces@gnso.icann.org> Kurt, This certainly seems like a good idea. I would suggest that the Board might want to appoint the liaison from Sub Pro. (Was that Avri?) The topic was covered so extensively in Sub Pro deliberations and the background on those discussions would be helpful. Anne Anne E. Aikman-Scalese Of Counsel AAikman@lewisroca.com<mailto:AAikman@lewisroca.com> D. 520.629.4428 [cid:image002.png@01D8F517.5F594B10] From: council <council-bounces@gnso.icann.org<mailto:council-bounces@gnso.icann.org>> On Behalf Of kurt kjpritz.com via council Sent: Wednesday, November 9, 2022 2:58 PM To: GNSO Council List <council@gnso.icann.org<mailto:council@gnso.icann.org>> Subject: [council] AOB - Board Liaison to Closed Generic discussion [EXTERNAL] ________________________________ Hi Councillors: I have been asked to nominate a brief discussion topic for AOB: the provision of a Board Liaison to the GAC-Council Closed Generics Team. This issue was discussed during a recent RySG meeting with the idea that a Board liaison would be beneficial. Some in that meeting thought that there was an existing provision for a Board liaison. In any case, there have have been no Board member attendance at the Closed Generics' meetings. For our Council discussion, I would like to get an understanding as to: * whether a Board liaison is already expected (and so we should remind the Board of this) * if not, whether we should request the Board to appoint a liaison (please check with your Closed Generic rep on this), and * to address an associated topic, whether the Board liaison should be dis-interested or new to the issue to provide an uncoloured perspective. If this can be simply settled or answered via an email discussion, that would be fine also. Thanks everyone and best regards, Kurt ________________________________ This message and any attachments are intended only for the use of the individual or entity to which they are addressed. If the reader of this message or an attachment is not the intended recipient or the employee or agent responsible for delivering the message or attachment to the intended recipient you are hereby notified that any dissemination, distribution or copying of this message or any attachment is strictly prohibited. If you have received this communication in error, please notify us immediately by replying to the sender. The information transmitted in this message and any attachments may be privileged, is intended only for the personal and confidential use of the intended recipients, and is covered by the Electronic Communications Privacy Act, 18 U.S.C. §2510-2521. Confidentiality Notice This message is intended exclusively for the individual or entity to which it is addressed. This communication may contain information that is proprietary, privileged, confidential or otherwise legally exempt from disclosure. If you are not the named addressee, you are not authorized to read, print, retain, copy or disseminate this message or any part of it. If you have received this message in error, please notify the sender immediately either by phone (800-237-2000) or reply to this e-mail and delete all copies of this message.
Thanks Kurt, I agree it seems likely to be helpful to have a Board Liaison to the Closed Generics group to help ensure greater visibility to the Board of the discussions which take place. In reaction to your suggestion Anne, whilst there are obvious benefits, in terms of knowing the background, to appointing a previous Board Liaison to SubPro, I think there could also be benefits to having a Board Liaison come to the Closed Generic discussion afresh. Regardless, I don't think that it is really our place to be suggesting who might be appointed as the Board Liaison, I think that needs to be a matter for the Board itself. Susan Payne Head of Legal Policy Com Laude T +44 (0) 20 7421 8250 Ext 255 [cid:image001.png@01D8F5F8.111912A0]<https://comlaude.com/> From: council <council-bounces@gnso.icann.org> On Behalf Of Aikman-Scalese, Anne via council Sent: 10 November 2022 00:32 To: kurt kjpritz.com <kurt@kjpritz.com>; GNSO Council List <council@gnso.icann.org> Subject: Re: [council] AOB - Board Liaison to Closed Generic discussion Kurt, This certainly seems like a good idea. I would suggest that the Board might want to appoint the liaison from Sub Pro. (Was that Avri?) The topic was covered so extensively in Sub Pro deliberations and the background on those discussions would be helpful. Anne Anne E. Aikman-Scalese Of Counsel AAikman@lewisroca.com<mailto:AAikman@lewisroca.com> D. 520.629.4428 [cid:image006.png@01D8F5F6.CEA21BC0] From: council <council-bounces@gnso.icann.org<mailto:council-bounces@gnso.icann.org>> On Behalf Of kurt kjpritz.com via council Sent: Wednesday, November 9, 2022 2:58 PM To: GNSO Council List <council@gnso.icann.org<mailto:council@gnso.icann.org>> Subject: [council] AOB - Board Liaison to Closed Generic discussion [EXTERNAL] ________________________________ Hi Councillors: I have been asked to nominate a brief discussion topic for AOB: the provision of a Board Liaison to the GAC-Council Closed Generics Team. This issue was discussed during a recent RySG meeting with the idea that a Board liaison would be beneficial. Some in that meeting thought that there was an existing provision for a Board liaison. In any case, there have have been no Board member attendance at the Closed Generics' meetings. For our Council discussion, I would like to get an understanding as to: * whether a Board liaison is already expected (and so we should remind the Board of this) * if not, whether we should request the Board to appoint a liaison (please check with your Closed Generic rep on this), and * to address an associated topic, whether the Board liaison should be dis-interested or new to the issue to provide an uncoloured perspective. If this can be simply settled or answered via an email discussion, that would be fine also. Thanks everyone and best regards, Kurt ________________________________ This message and any attachments are intended only for the use of the individual or entity to which they are addressed. If the reader of this message or an attachment is not the intended recipient or the employee or agent responsible for delivering the message or attachment to the intended recipient you are hereby notified that any dissemination, distribution or copying of this message or any attachment is strictly prohibited. If you have received this communication in error, please notify us immediately by replying to the sender. The information transmitted in this message and any attachments may be privileged, is intended only for the personal and confidential use of the intended recipients, and is covered by the Electronic Communications Privacy Act, 18 U.S.C. §2510-2521. ________________________________ The contents of this email and any attachments are confidential to the intended recipient. They may not be disclosed, used by or copied in any way by anyone other than the intended recipient. If you have received this message in error, please return it to the sender (deleting the body of the email and attachments in your reply) and immediately and permanently delete it. Please note that Com Laude Group Limited (the "Com Laude Group") does not accept any responsibility for viruses and it is your responsibility to scan or otherwise check this email and any attachments. The Com Laude Group does not accept liability for statements which are clearly the sender's own and not made on behalf of the group or one of its member entities. The Com Laude Group is a limited company registered in England and Wales with company number 10689074 and registered office at 28-30 Little Russell Street, London, WC1A 2HN England. The Com Laude Group includes Nom-IQ Limited t/a Com Laude, a company registered in England and Wales with company number 5047655 and registered office at 28-30 Little Russell Street, London, WC1A 2HN England; Valideus Limited, a company registered in England and Wales with company number 6181291 and registered office at 28-30 Little Russell Street, London, WC1A 2HN England; Demys Limited, a company registered in Scotland with company number SC197176 and registered office at 15 William Street, South West Lane, Edinburgh, EH3 7LL Scotland; Consonum, Inc. dba Com Laude USA and Valideus USA, a corporation incorporated in the State of Washington and principal office address at Suite 332, Securities Building, 1904 Third Ave, Seattle, WA 98101; Com Laude (Japan) Corporation, a company registered in Japan with company number 0100-01-190853 and registered office at 1-3-21 Shinkawa, Chuo-ku, Tokyo, 104-0033, Japan; Com Laude Domain ESP S.L.U., a company registered in Spain and registered office address at Calle Barcas 2, 2, Valencia, 46002, Spain. For further information see www.comlaude.com<https://comlaude.com>
HI Susan. I agree 100% with your observations here. Anne Anne E. Aikman-Scalese Of Counsel AAikman@lewisroca.com<mailto:AAikman@lewisroca.com> D. 520.629.4428 [cid:image003.png@01D8F824.69B01C50] From: Susan Payne <susan.payne@comlaude.com> Sent: Friday, November 11, 2022 11:05 AM To: Aikman-Scalese, Anne <AAikman@lewisroca.com>; kurt kjpritz.com <kurt@kjpritz.com>; GNSO Council List <council@gnso.icann.org> Subject: RE: AOB - Board Liaison to Closed Generic discussion [EXTERNAL] ________________________________ Thanks Kurt, I agree it seems likely to be helpful to have a Board Liaison to the Closed Generics group to help ensure greater visibility to the Board of the discussions which take place. In reaction to your suggestion Anne, whilst there are obvious benefits, in terms of knowing the background, to appointing a previous Board Liaison to SubPro, I think there could also be benefits to having a Board Liaison come to the Closed Generic discussion afresh. Regardless, I don't think that it is really our place to be suggesting who might be appointed as the Board Liaison, I think that needs to be a matter for the Board itself. Susan Payne Head of Legal Policy Com Laude T +44 (0) 20 7421 8250 Ext 255 [cid:image004.png@01D8F824.69B01C50]<https://comlaude.com/> From: council <council-bounces@gnso.icann.org<mailto:council-bounces@gnso.icann.org>> On Behalf Of Aikman-Scalese, Anne via council Sent: 10 November 2022 00:32 To: kurt kjpritz.com <kurt@kjpritz.com<mailto:kurt@kjpritz.com>>; GNSO Council List <council@gnso.icann.org<mailto:council@gnso.icann.org>> Subject: Re: [council] AOB - Board Liaison to Closed Generic discussion Kurt, This certainly seems like a good idea. I would suggest that the Board might want to appoint the liaison from Sub Pro. (Was that Avri?) The topic was covered so extensively in Sub Pro deliberations and the background on those discussions would be helpful. Anne Anne E. Aikman-Scalese Of Counsel AAikman@lewisroca.com<mailto:AAikman@lewisroca.com> D. 520.629.4428 [cid:image003.png@01D8F824.69B01C50] From: council <council-bounces@gnso.icann.org<mailto:council-bounces@gnso.icann.org>> On Behalf Of kurt kjpritz.com via council Sent: Wednesday, November 9, 2022 2:58 PM To: GNSO Council List <council@gnso.icann.org<mailto:council@gnso.icann.org>> Subject: [council] AOB - Board Liaison to Closed Generic discussion [EXTERNAL] ________________________________ Hi Councillors: I have been asked to nominate a brief discussion topic for AOB: the provision of a Board Liaison to the GAC-Council Closed Generics Team. This issue was discussed during a recent RySG meeting with the idea that a Board liaison would be beneficial. Some in that meeting thought that there was an existing provision for a Board liaison. In any case, there have have been no Board member attendance at the Closed Generics' meetings. For our Council discussion, I would like to get an understanding as to: * whether a Board liaison is already expected (and so we should remind the Board of this) * if not, whether we should request the Board to appoint a liaison (please check with your Closed Generic rep on this), and * to address an associated topic, whether the Board liaison should be dis-interested or new to the issue to provide an uncoloured perspective. If this can be simply settled or answered via an email discussion, that would be fine also. Thanks everyone and best regards, Kurt ________________________________ This message and any attachments are intended only for the use of the individual or entity to which they are addressed. If the reader of this message or an attachment is not the intended recipient or the employee or agent responsible for delivering the message or attachment to the intended recipient you are hereby notified that any dissemination, distribution or copying of this message or any attachment is strictly prohibited. If you have received this communication in error, please notify us immediately by replying to the sender. The information transmitted in this message and any attachments may be privileged, is intended only for the personal and confidential use of the intended recipients, and is covered by the Electronic Communications Privacy Act, 18 U.S.C. §2510-2521. ________________________________ The contents of this email and any attachments are confidential to the intended recipient. They may not be disclosed, used by or copied in any way by anyone other than the intended recipient. If you have received this message in error, please return it to the sender (deleting the body of the email and attachments in your reply) and immediately and permanently delete it. Please note that Com Laude Group Limited (the "Com Laude Group") does not accept any responsibility for viruses and it is your responsibility to scan or otherwise check this email and any attachments. The Com Laude Group does not accept liability for statements which are clearly the sender's own and not made on behalf of the group or one of its member entities. The Com Laude Group is a limited company registered in England and Wales with company number 10689074 and registered office at 28-30 Little Russell Street, London, WC1A 2HN England. The Com Laude Group includes Nom-IQ Limited t/a Com Laude, a company registered in England and Wales with company number 5047655 and registered office at 28-30 Little Russell Street, London, WC1A 2HN England; Valideus Limited, a company registered in England and Wales with company number 6181291 and registered office at 28-30 Little Russell Street, London, WC1A 2HN England; Demys Limited, a company registered in Scotland with company number SC197176 and registered office at 15 William Street, South West Lane, Edinburgh, EH3 7LL Scotland; Consonum, Inc. dba Com Laude USA and Valideus USA, a corporation incorporated in the State of Washington and principal office address at Suite 332, Securities Building, 1904 Third Ave, Seattle, WA 98101; Com Laude (Japan) Corporation, a company registered in Japan with company number 0100-01-190853 and registered office at 1-3-21 Shinkawa, Chuo-ku, Tokyo, 104-0033, Japan; Com Laude Domain ESP S.L.U., a company registered in Spain and registered office address at Calle Barcas 2, 2, Valencia, 46002, Spain. For further information see www.comlaude.com<https://comlaude.com> ________________________________ This message and any attachments are intended only for the use of the individual or entity to which they are addressed. If the reader of this message or an attachment is not the intended recipient or the employee or agent responsible for delivering the message or attachment to the intended recipient you are hereby notified that any dissemination, distribution or copying of this message or any attachment is strictly prohibited. If you have received this communication in error, please notify us immediately by replying to the sender. The information transmitted in this message and any attachments may be privileged, is intended only for the personal and confidential use of the intended recipients, and is covered by the Electronic Communications Privacy Act, 18 U.S.C. §2510-2521.
participants (4)
-
Aikman-Scalese, Anne -
John McElwaine -
kurt kjpritz.com -
Susan Payne